A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Christoph K. Stein‐Thoeringer(Cornell University), Eran Elinav(German Cancer Research Center), Kayla Reid(Moffitt Cancer Center), Marion Subklewe(LMU Klinikum), Michael D. Jain(Moffitt Cancer Center), Tomo Hayase(The University of Texas MD Anderson Cancer Center), Ivonne I. Flores(The University of Texas MD Anderson Cancer Center), Raphaël Steiner(The University of Texas MD Anderson Cancer Center), Matthias Fante(Universitätsklinikum Würzburg), Michael Schmitt(German Cancer Research Center), Frederick L. Locke(Moffitt Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Eiko Hayase(The University of Texas MD Anderson Cancer Center), Robert R. Jenq(City Of Hope National Medical Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Carsten Müller‐Tidow(Heidelberg University), Luis Fayad(The University of Texas MD Anderson Cancer Center), Roman Rohrbach(German Cancer Research Center), Joel G. Turner(The Royal Free Hospital), Uria Mor(Weizmann Institute of Science), Daniel Wolff(University Hospital Regensburg), Neeraj Saini(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Melanie J. Hidalgo-Vargas(Moffitt Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Marco L. Davila(University of South Florida), Hendrik Poeck(University Hospital Regensburg), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Lauren McDaniel(The University of Texas MD Anderson Cancer Center), Dai Chihara(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Reetakshi Arora(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Viktoria Blumenberg(German Cancer Research Center), Rogier Gaiser(German Cancer Research Center), Martin Heidenreich(German Cancer Research Center), Meghan Menges(Moffitt Cancer Center), Chia‐Chi Chang(The University of Texas MD Anderson Cancer Center), Matthias Edinger(University Hospital Regensburg), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Peter Dreger(Heidelberg University), Sabine Schmidt(Centre National de la Recherche Scientifique), Michael Wang(St. Joseph Health System), Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Eli Zamir(German Cancer Research Center), Anita Schmitt(Heidelberg University), Maria‐Luisa Schubert(Heidelberg University)
Cited by 226
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Interaction between microbiota and immunity in health and disease
|Cell Research|2020|3.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k